Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2.
Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2.
复制标题
DOI:
10.1038/s41598-020-74761-y
复制
发表时间:
2020-10-20
影响因子:
4.6
通讯作者:
Liu Y
中科院分区:
文献类型:
--
作者:
Dong J;Huang B;Wang B;Titong A;Gallolu Kankanamalage S;Jia Z;Wright M;Parthasarathy P;Liu Y
SARS-CoV-2 is a newly emergent coronavirus, which has adversely impacted human health and has led to the COVID-19 pandemic. There is an unmet need to develop therapies against SARS-CoV-2 due to its severity and lack of treatment options. A promising approach to combat COVID-19 is through the neutralization of SARS-CoV-2 by therapeutic antibodies. Previously, we described a strategy to rapidly identify and generate llama nanobodies (VHH) from naïve and synthetic humanized VHH phage libraries that specifically bind the S1 SARS-CoV-2 spike protein, and block the interaction with the human ACE2 receptor. In this study we used computer-aided design to construct multi-specific VHH antibodies fused to human IgG1 Fc domains based on the epitope predictions for leading VHHs. The resulting tri-specific VHH-Fc antibodies show more potent S1 binding, S1/ACE2 blocking, and SARS-CoV-2 pseudovirus neutralization than the bi-specific VHH-Fcs or combination of individual monoclonal VHH-Fcs. Furthermore, protein stability analysis of the VHH-Fcs shows favorable developability features, which enable them to be quickly and successfully developed into therapeutics against COVID-19.
登录
查看更多内容
影响因子:
3.7
作者:
Beard H;Cholleti A;Pearlman D;Sherman W;Loving KA
通讯作者:
Loving KA
影响因子:
64.8
作者:
Li W;Moore MJ;Vasilieva N;Sui J;Wong SK;Berne MA;Somasundaran M;Sullivan JL;Luzuriaga K;Greenough TC;Choe H;Farzan M
通讯作者:
Farzan M
影响因子:
8
作者:
Dumoulin, M;Conrath, K;Matagne, A
通讯作者:
Matagne, A
影响因子:
16.8
作者:
Huo, Jiangdong;Le Bas, Audrey;Naismith, James H.
通讯作者:
Naismith, James H.
影响因子:
56.9
作者:
HOLLAND, J;SPINDLER, K;VANDEPOL, S
通讯作者:
VANDEPOL, S